Original articleTravoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension☆
Section snippets
Patients and methods
This was a randomized, multicenter, double-masked, active-controlled, parallel group study conducted in accordance with the ethical principles set forth in the Declaration of Helsinki. Eight hundred one patients were randomized to one of four treatment groups in an approximate 1:1:1:1 ratio, (travoprost 0.0015%, n = 205; travoprost 0.004%, n = 200; timolol, n = 200; latanoprost, n = 196). The Alcon Biostatistics Department prepared the computer-generated randomization schedule. All patients
Results
Eight hundred one patients were randomized to one of four treatments. All 801 patients were included in the safety analysis. Fourteen patients were excluded from the intent-to-treat analysis because of no on-treatment visit data (travoprost 0.0015% − N = 3; travoprost 0.004% − N = 3; latanoprost − N = 3; timolol − N = 5) resulting in 787 patients in the intent-to-treat data set. Forty-one patients were excluded from the per protocol analysis (travoprost 0.005% − N = 7; travoprost 0.004% − N =
Discussion
When used as primary therapy, the results of this study show that both concentrations of travoprost (0.0015% and 0.004%) were equal or superior to latanoprost and superior to timolol in lowering intraocular pressure at all treatment visits in patients with open-angle glaucoma and ocular hypertension.
In studies carried out in the laser monkey model, reductions in intraocular pressure were observed beginning 2 hours after administration of travoprost and peaked by 12 to 20 hours after dose.5
References (16)
- et al.
The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eiconoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester
Exp Eye Res
(1987) - et al.
Blindness from glaucoma
Am J Ophthalmol
(1975) - et al.
Race and primary open-angle glaucoma
Am J Ophthalmol
(1985) - et al.
Prostaglandin analogs
- et al.
[3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor
J Pharm Pharmacol
(1999) - et al.
Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology
J Ocul Pharmacol Ther
(1999) - Hellberg MR, Sallee V, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP...
- et al.
Travoprosta new once-daily dosed prostaglandin for the reduction of elevated intraocular pressure
Invest Ophthalmol Vis Sci
(1999)
Cited by (413)
smProdrugs: A repository of small molecule prodrugs
2023, European Journal of Medicinal ChemistryAdvances in the discovery of novel agents for the treatment of glaucoma: The role of nitric oxide donors
2023, Nitric Oxide in Health and Disease: Therapeutic Applications in Cancer and Inflammatory DisordersComplications and adverse effects of periocular aesthetic treatments
2022, Survey of OphthalmologyRu-Catalyzed Defluorinative Alkylation or Catalyst-Free Hydroalkylation of gem-Difluoroalkenes Enabled by Visible Light
2022, Journal of Organic ChemistryGlaucoma
2022, Comprehensive PharmacologyA comparison between the effect of topical tafluprost and latanoprost on intraocular pressure in healthy male guinea pigs
2021, Journal of Exotic Pet Medicine
- ☆
This study was supported by Alcon Research, Ltd. Dr Netland was a clinical investigator for this study and has no proprietary interest in travoprost or any other product in this manuscript. Proprietary rights for travoprost are retained by Alcon Research, Ltd, 6201 S. Freeway, Fort Worth, Texas 76134.